Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport

[1]  H. Fujino,et al.  Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. , 2011, Arzneimittel-Forschung.

[2]  S. Kaneko,et al.  Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. , 2005, British journal of clinical pharmacology.

[3]  A. Rettie,et al.  Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance , 2005, Clinical pharmacology and therapeutics.

[4]  T. Sakaeda,et al.  Pharmacogenomics of MDR and MRP subfamilies. , 2004, Personalized medicine.

[5]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[6]  T. Miida,et al.  Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. , 2004, Journal of atherosclerosis and thrombosis.

[7]  Y. Sugiyama,et al.  Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.

[8]  T. Sakaeda,et al.  Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. , 2004, Current topics in medicinal chemistry.

[9]  E. Bates,et al.  Clinical significance of the atorvastatin-clopidogrel drug-drug interaction. , 2004, Circulation.

[10]  Yan Zhang,et al.  Tissue Doppler Imaging Is Superior to Strain Rate Imaging and Postsystolic Shortening on the Prediction of Reverse Remodeling in Both Ischemic and Nonischemic Heart Failure After Cardiac Resynchronization Therapy , 2004, Circulation.

[11]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.

[12]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[13]  Paul D. Martin,et al.  The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. , 2004, British journal of clinical pharmacology.

[14]  Miranda R Andrus,et al.  Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature , 2004, Pharmacotherapy.

[15]  M. Barry.  Rosuvastatin — warfarin drug interaction , 2004, The Lancet.

[16]  T. Sakaeda,et al.  Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  L. Benet,et al.  Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. , 2003, Current drug metabolism.

[18]  Amy Roe,et al.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[19]  H. Fujino,et al.  Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[20]  Amy Roe,et al.  The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective , 2003, Journal of clinical pharmacology.

[21]  U. Laufs.  Beyond lipid-lowering: effects of statins on endothelial nitric oxide , 2003, European Journal of Clinical Pharmacology.

[22]  H. Fujino,et al.  Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  J. Miners,et al.  Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. , 2002, Toxicology.

[24]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[25]  P. Neuvonen,et al.  Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[26]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[27]  Y. Tanigawara,et al.  Simvastatin and lovastatin, but not pravastatin, interact with MDR1 , 2002, The Journal of pharmacy and pharmacology.

[28]  H. Fujino,et al.  Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay--inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[29]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption. , 2001, Advanced drug delivery reviews.

[30]  P. Neuvonen,et al.  Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.

[31]  P. Neuvonen,et al.  Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.

[32]  P. Neuvonen,et al.  Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.

[33]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[34]  T. Ebner,et al.  Assessment of microsomal tolbutamide hydroxylation by a simple thin-layer chromatography radioactivity assay. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[35]  R. Stern,et al.  Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin , 1997, Journal of clinical pharmacology.

[36]  K. Tanaka,et al.  Effect of Cyclosporin Analogues and FK506 on Transcellular Transport of Daunorubicin and Vinblastine via P-glycoprotein , 1996, Pharmaceutical Research.

[37]  L. Benet,et al.  Active secretion and enterocytic drug metabolism barriers to drug absorption 1 PII of original artic , 1996 .

[38]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[39]  Y. Tanigawara,et al.  Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. , 1993, The Journal of pharmacology and experimental therapeutics.

[40]  Y. Tanigawara,et al.  Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. , 1993, The Journal of pharmacology and experimental therapeutics.

[41]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[42]  Y. Tanigawara,et al.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). , 1992, The Journal of pharmacology and experimental therapeutics.

[43]  M C Willingham,et al.  Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[44]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Gordon M. Crippen,et al.  Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions , 1987, J. Chem. Inf. Comput. Sci..

[46]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[47]  I. Pastan,et al.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. P. Shea,et al.  A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450. , 1985, Analytical biochemistry.

[49]  Jiunn H. Lin,et al.  Role of P-Glycoprotein in Pharmacokinetics , 2003, Clinical pharmacokinetics.

[50]  M. Yoshida.  Potential role of statins in inflammation and atherosclerosis. , 2003, Journal of atherosclerosis and thrombosis.

[51]  R. Schmieder,et al.  Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.